Client:

GluBio Therapeutics Inc

Challenge:

GluBio Therapeutics Inc, a biotech company focusing on Targeted Protein Degradation (TPD) drug discovery and development, routinely analyzed whole cell proteomes under varying conditions to identify ideal drug candidates. The complexity and specificity of their research required a highly accurate and versatile mass spectrometry service.

Solution:

Innomics' Mass Spec proteomics services offered the precision and flexibility GluBio needed. Tailored specifically to GluBio's requirements, Innomics' TMT proteomics assay became an integral part of their robust drug discovery platform.

Results:

• Successful integration of Innomics’ Mass Spec services into GluBio’s TPD drug development process.
• Accelerated progression of drug programs in the pipeline, thanks to clear data and biological insights provided by Innomics.
• Ability to progress preclinical projects on or ahead of schedule, leveraging Innomics’ rapid turnaround times.

Why Innomics?

• Expertise in Mass Spectrometry: Innomics’ proficiency in delivering high-quality mass spectrometry services matched GluBio's high standards for research.
• Customer-Centric Approach: Innomics demonstrated a deep understanding of GluBio’s needs, providing customized solutions and exceeding expectations.
• Speed and Efficiency: The quick turnaround time from sample reception to detailed data reporting significantly accelerated GluBio's research processes.

Looking Ahead:

GluBio is enthusiastic about the future of TPD drug discovery and development. This innovative approach allows them to target previously 'undruggable' disease targets, opening new avenues in therapeutic development. The success with oncology-focused TPD research has paved the way for GluBio to expand into other areas, such as their emerging sickle-cell disease program. Innomics will offer a comprehensive TPD solution via proteomics analysis assay based on high-resolution mass spectrometry for protein degradation drugs.

Conclusion:

Innomics’ Mass Spec services have not only met but also elevated GluBio's drug discovery and development process. This collaboration is a strong demonstration of how state-of-the-art technology when paired with expert service and swift execution, can truly propel pharmaceutical research and development to new heights.